Clinical Trial Update: Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 clinical trial tested erlotinib alone or with cixutumumab in patients with stage III or stage IV non-small cell lung cancer; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cixutumumab (Cixutumumab)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-04-23